Please Wait.....
Report
Insulin Delivery Device - Company Evaluation Report, 2025
Market Report I 2025-08-01 I 154 Pages I MarketsandMarkets
The Insulin Delivery Devices Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Insulin Delivery Devices. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 240 companies, of which the Top 25 Insulin Delivery Devices Companies were categorized and recognized as quadrant leaders.
Insulin delivery devices such as pens, pen needles, syringes, and pumps are essential tools for diabetes patients to control their blood glucose levels. This dominance is attributed to the increasing preference for insulin pens among diabetic patients due to their ease of use, improved convenience, reduced pain during administration, enhanced dosage accuracy, and improved medication adherence.
The growth of the insulin delivery devices market is primarily driven by the rising prevalence of diabetes, ongoing technological advancements in insulin delivery solutions, and supportive government initiatives coupled with favourable reimbursement policies. These factors collectively contribute to the increasing adoption of insulin delivery devices worldwide.
The 360 Quadrant maps the Insulin Delivery Devices companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Insulin Delivery Devices quadrant. The top criteria for product footprint evaluation included By Type (Insulin Pens, Insulin Pumps, Insulin Pen Needles, Insulin Syringes, Other Insulin Delivery Devices), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), and By End User (Home Care Settings, Hospitals & Clinics, Other End Users).
Key Players
Key players in the Insulin Delivery Devices market include major global corporations and specialized innovators such as Embecta Corp. (US), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Ypsomed (Switzerland), Eli Lilly and Company (US), Tandem Diabetes Care, Inc. (US), Roche Diabetes Care (Switzerland), HTL-STREFA , a subsidiary of MTD Group (Poland), Terumo Corporation (Japan), Eoflow Co., Ltd (South Korea), B. Braun SE (Germany), Haselmeier , a subsidiary of Medmix (Germany), Insulet Corporation (US), Biocon (India), Nipro (Japan), Sooil Developments Co., Ltd (South Korea), Wockhardt (India), MannKind Corporation (US), Medtrum Technologies Inc. (China), CeQur Corporation (Switzerland), Hindustan Syringes & Medical Devices Ltd (India), Sungshim Medical Co., Ltd (South Korea), Debiotech SA (Switzerland), and Jiangsu Delfu Medical Co., Ltd (China). These companies are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation, expand their global footprint, and maintain a competitive edge in this rapidly evolving market.
Top 3 Companies
Embecta Corp.
Embecta Corp. was established on April 1, 2022, as a spin-off from Becton, Dickinson and Company (BD), inheriting BD's legacy in diabetes care. As a global leader in medical devices, Embecta focuses exclusively on delivering diabetes care solutions aimed at improving patient health and quality of life. Its product portfolio includes a comprehensive range of pen needles, syringes, and safety injection devices. Embecta supports its global operations through a robust manufacturing, commercial, and distribution infrastructure.
Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company renowned for its leadership in diabetes care. The company operates through two main business segments: Diabetes and Obesity Care and Rare Disease (formerly known as Biopharm). The company also provides innovative digital tools for diabetes management, including smart insulin pens and Dose Check, a digital application for insulin dose guidance. It maintains a robust global presence, with offices in 80 countries and product distribution spanning over 170 markets, reinforcing its commitment to improving the lives of people living with diabetes and related conditions worldwide.
Ypsomed
Ypsomed is a leading developer and manufacturer of injection and infusion systems for self-medication, with more than 40 years of experience and recognized expertise in diabetes care. The company is an independent industry leader in the production of injection pens for pharmaceutical and biotechnology companies, as well as diabetes-focused products such as insulin pumps, pen needles, and blood glucose monitoring systems.
1 INTRODUCTION 13
1.1 MARKET DEFINITION 13
1.2 INCLUSION AND EXCLUSIONS 13
1.3 STAKEHOLDERS 14
2 EXECUTIVE SUMMARY 15
3 MARKET OVERVIEW 19
3.1 INTRODUCTION 19
3.2 MARKET DYNAMICS 19
3.2.1 DRIVERS 20
3.2.1.1 Growth in prevalence of diabetic population 20
3.2.1.2 Technological advancements in insulin delivery devices 21
3.2.1.3 Government support and favorable reimbursement schemes to
favor the market growth 23
3.2.2 RESTRAINTS 23
3.2.2.1 High cost and lack of reimbursement in emerging economies 23
3.2.2.2 Needle anxiety in patients to affect growth of pen needles and syringes market 24
3.2.2.3 Oral insulin as alternative drug delivery method 24
3.2.3 OPPORTUNITIES 25
3.2.3.1 Increase in research & development activities and
strategic partnerships 25
3.2.3.2 Increase in healthcare expenditure on diabetes care 26
3.2.3.3 Advances in insulin syringe and needle technology 26
3.2.3.4 Mandates pertaining to safety-engineered medical needles 27
3.2.4 CHALLENGES 27
3.2.4.1 Needlestick injuries and misuse of injection pens 27
3.2.4.2 Lack of interoperability among insulin delivery devices 28
3.3 INDUSTRY TRENDS 29
3.3.1 GROWING DEMAND FOR HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS 29
3.3.2 SYNCHRONIZATION OF SMART INSULIN PENS WITH CONTINUOUS GLUCOSE MONITORING SYSTEMS PROMOTES DIABETES DATA SHARING 30
3.3.3 INCREASE IN NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS 31
3.4 TECHNOLOGY ANALYSIS 31
3.4.1 KEY TECHNOLOGIES 31
3.4.1.1 Automated insulin delivery 31
3.4.2 COMPLEMENTARY TECHNOLOGIES 32
3.4.2.1 Bluetooth 32
3.4.3 ADJACENT TECHNOLOGIES 32
3.4.3.1 Continuous glucose monitoring 32
3.5 KEY CONFERENCES & EVENTS 33
3.6 PATENT ANALYSIS 34
3.6.1 PATENT PUBLICATION TRENDS FOR INSULIN DELIVERY DEVICES 34
3.6.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN INSULIN DELIVERY DEVICES MARKET 34
3.7 ECOSYSTEM MARKET MAP 37
3.8 PORTER'S FIVE FORCES ANALYSIS 39
3.8.1 INTENSITY OF COMPETITIVE RIVALRY 40
3.8.2 BARGAINING POWER OF SUPPLIERS 40
3.8.3 BARGAINING POWER OF BUYERS 40
3.8.4 THREAT OF SUBSTITUTES 41
3.8.5 THREAT OF NEW ENTRANTS 41
3.9 TRENDS/DISRUPTION IMPACTING CUSTOMER'S BUSINESS 41
3.10 IMPACT OF AI/GENERATIVE AI ON INSULIN DELIVERY DEVICES MARKET 42
4 COMPETITIVE LANDSCAPE 43
4.1 INTRODUCTION 43
4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 43
4.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
INSULIN DELIVERY DEVICES MARKET 43
4.3 REVENUE ANALYSIS, 2022-2024 45
4.4 MARKET SHARE ANALYSIS, 2024 45
4.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 47
4.5.1 STARS 48
4.5.2 EMERGING LEADERS 48
4.5.3 PERVASIVE PLAYERS 48
4.5.4 PARTICIPANTS 48
4.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 50
4.5.5.1 Company footprint 50
4.5.5.2 Type footprint 51
4.5.5.3 Region footprint 52
4.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 53
4.6.1 PROGRESSIVE COMPANIES 53
4.6.2 RESPONSIVE COMPANIES 53
4.6.3 DYNAMIC COMPANIES 53
4.6.4 STARTING BLOCKS 53
4.6.5 COMPETITIVE BENCHMARKING 55
4.6.5.1 Detailed list of key startups/SMEs, 2024 55
4.6.5.2 Competitive benchmarking of key startups/SMEs 56
?
4.7 BRAND/PRODUCT COMPARISON 57
4.8 COMPANY VALUATION & FINANCIAL METRICS 58
4.8.1 FINANCIAL METRICS 58
4.8.2 COMPANY VALUATION 58
4.9 R&D ASSESSMENT OF KEY PLAYERS 59
4.10 COMPETITIVE SCENARIO 59
4.10.1 PRODUCT LAUNCHES & APPROVALS 59
4.10.2 DEALS 66
4.10.3 EXPANSIONS 72
4.10.4 OTHER DEVELOPMENTS 75
5 COMPANY PROFILES 77
5.1 KEY PLAYERS 77
5.1.1 EMBECTA CORP. (FORMERLY BECTON, DICKINSON AND
COMPANY DIABETES CARE BUSINESS) 77
5.1.1.1 Business overview 77
5.1.1.2 Products offered 78
5.1.1.3 Recent developments 79
5.1.1.3.1 Product launches and approvals 79
5.1.1.3.2 Deals 79
5.1.1.3.3 Expansions 80
5.1.1.3.4 Other developments 80
5.1.1.4 MnM view 80
5.1.1.4.1 Right to win 80
5.1.1.4.2 Strategic choices 81
5.1.1.4.3 Weaknesses & competitive threats 81
5.1.2 NOVO NORDISK A/S 82
5.1.2.1 Business overview 82
5.1.2.2 Products offered 83
5.1.2.3 Recent developments 84
5.1.2.3.1 Product launches and approvals 84
5.1.2.3.2 Deals 84
5.1.2.3.3 Other developments 86
5.1.2.4 MnM view 87
5.1.2.4.1 Right to win 87
5.1.2.4.2 Strategic choices 87
5.1.2.4.3 Weaknesses & competitive threats 87
5.1.3 MEDTRONIC 88
5.1.3.1 Business overview 88
5.1.3.2 Products offered 89
5.1.3.3 Recent developments 90
5.1.3.3.1 Product launches and approvals 90
5.1.3.3.2 Deals 91
5.1.3.3.3 Expansions 92
5.1.3.3.4 Other developments 92
5.1.3.4 MnM view 92
5.1.3.4.1 Right to win 92
5.1.3.4.2 Strategic choices 93
5.1.3.4.3 Weaknesses & competitive threats 93
5.1.4 SANOFI 94
5.1.4.1 Business overview 94
5.1.4.2 Products offered 95
5.1.4.3 Recent developments 96
5.1.4.3.1 Product launches and approvals 96
5.1.4.3.2 Expansions 96
5.1.4.3.3 Other developments 97
5.1.4.4 MnM view 97
5.1.4.4.1 Right to win 97
5.1.4.4.2 Strategic choices 97
5.1.4.4.3 Weaknesses & competitive threats 98
5.1.5 ELI LILLY AND COMPANY 99
5.1.5.1 Business overview 99
5.1.5.2 Products offered 100
5.1.5.3 Recent developments 101
5.1.5.3.1 Product launches and approvals 101
5.1.5.3.2 Deals 101
5.1.5.3.3 Expansions 102
5.1.5.3.4 Other developments 102
5.1.5.4 MnM view 103
5.1.5.4.1 Right to win 103
5.1.5.4.2 Strategic choices 103
5.1.5.4.3 Weaknesses and competitive threats 103
5.1.6 TANDEM DIABETES CARE, INC. 104
5.1.6.1 Business overview 104
5.1.6.2 Products offered 105
5.1.6.3 Recent developments 106
5.1.6.3.1 Product launches and approvals 106
5.1.6.3.2 Deals 107
5.1.7 INSULET CORPORATION 108
5.1.7.1 Business overview 108
5.1.7.2 Products offered 109
5.1.7.3 Recent developments 109
5.1.7.3.1 Product launches and approvals 109
5.1.7.3.2 Deals 111
5.1.7.3.3 Expansions 112
5.1.7.3.4 Other developments 112
5.1.8 BIOCON 113
5.1.8.1 Business overview 113
5.1.8.2 Products offered 114
5.1.8.3 Recent developments 115
5.1.8.3.1 Deals 115
5.1.8.3.2 Other developments 115
5.1.9 ROCHE DIABETES CARE 116
5.1.9.1 Business overview 116
5.1.9.2 Products offered 117
5.1.9.3 Recent developments 118
5.1.9.3.1 Product launches and approvals 118
5.1.10 HTL-STREFA (SUBSIDIARY OF THE MTD GROUP) 119
5.1.10.1 Business overview 119
5.1.10.2 Products offered 120
5.1.10.3 Recent developments 120
5.1.10.3.1 Deals 120
5.1.11 YPSOMED 121
5.1.11.1 Business overview 121
5.1.11.2 Products offered 122
5.1.11.3 Recent developments 123
5.1.11.3.1 Product launches and approvals 123
5.1.11.3.2 Deals 124
5.1.11.3.3 Expansions 125
5.1.11.3.4 Other developments 126
5.1.12 MEDTRUM TECHNOLOGIES INC. 127
5.1.12.1 Business overview 127
5.1.12.2 Products offered 127
5.1.13 TERUMO CORPORATION 128
5.1.13.1 Business overview 128
5.1.13.2 Products offered 129
5.1.13.3 Recent developments 130
5.1.13.3.1 Product launches and approvals 130
5.1.13.3.2 Deals 130
5.1.13.3.3 Expansions 131
5.1.13.3.4 Other developments 131
5.1.14 WOCKHARDT LIMITED 132
5.1.14.1 Business overview 132
5.1.14.2 Products offered 133
5.1.14.3 Recent developments 133
5.1.14.3.1 Product launches and approvals 133
5.1.14.3.2 Other developments 134
5.1.15 NIPRO 135
5.1.15.1 Business overview 135
5.1.15.2 Products offered 136
5.1.15.3 Recent developments 137
5.1.15.3.1 Expansions 137
5.2 OTHER PLAYERS 138
5.2.1 CEQUR CORPORATION 138
5.2.2 EOFLOW CO., LTD. 139
5.2.3 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD 140
5.2.4 SOOIL DEVELOPMENTS CO., LTD 141
5.2.5 SUNGSHIM MEDICAL CO., LTD. 142
5.2.6 B.BRAUN SE 143
5.2.7 DEBIOTECH SA 144
5.2.8 JIANGSU DELFU MEDICAL DEVICE CO., LTD 144
5.2.9 HASELMEIER (A SUBSIDIARY OF MEDMIX) 146
5.2.10 MANNKIND CORPORATION 147
6 APPENDIX 148
6.1 RESEARCH METHODOLOGY 148
6.1.1 RESEARCH DATA 148
6.1.1.1 Secondary data 148
6.1.1.2 Primary data 149
6.1.2 ASSUMPTIONS FOR STUDY 150
6.1.3 RESEARCH LIMITATIONS 150
6.1.4 RISK ASSESSMENT 151
6.2 COMPANY EVALUATION MATRIX: METHODOLOGY 151
6.3 AUTHOR DETAILS 154
TABLE 1 TOP 10 COUNTRIES/TERRITORIES WITH HIGHEST NUMBER OF ADULTS
(20-79 YEARS) WITH DIABETES, 2024 AND 2050 (MILLION) 21
TABLE 2 TOTAL DIABETES-RELATED HEALTH EXPENDITURE ACROSS REGIONS,
2024 AND 2050 (USD MILLION) 26
TABLE 3 HYBRID CLOSED-LOOP SYSTEMS: CURRENT MARKET SCENARIO 29
TABLE 4 MAJOR SMART INSULIN PENS AVAILABLE GLOBALLY 30
TABLE 5 RECENT COLLABORATIONS IN INSULIN DELIVERY DEVICE MARKET 31
TABLE 6 INSULIN DELIVERY DEVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2025-2026 33
TABLE 7 LIST OF PATENTS IN INSULIN DELIVERY DEVICES MARKET, 2022?2024 36
TABLE 8 INSULIN DELIVERY DEVICES MARKET: PORTER'S FIVE FORCES ANALYSIS 39
TABLE 9 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN INSULIN DELIVERY DEVICES MARKET 43
TABLE 10 INSULIN DELIVERY DEVICE MARKET: DEGREE OF COMPETITION 46
TABLE 11 INSULIN DELIVERY DEVICES MARKET: TYPE FOOTPRINT, 2024 51
TABLE 12 INSULIN DELIVERY DEVICES MARKET: REGION FOOTPRINT, 2024 52
TABLE 13 INSULIN DELIVERY DEVICES MARKET: DETAILED LIST OF
KEY STARTUPS/SMES, 2024 55
TABLE 14 INSULIN DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF
KEY STARTUPS/SMES, 2024 56
TABLE 15 INSULIN DELIVERY DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025 59
TABLE 16 INSULIN DELIVERY DEVICES MARKET: DEALS, JANUARY 2022-APRIL 2025 66
TABLE 17 INSULIN DELIVERY DEVICES MARKET: EXPANSIONS, JANUARY 2022-APRIL 2025 72
TABLE 18 INSULIN DELIVERY DEVICES MARKET: OTHER DEVELOPMENTS,
JANUARY 2022-APRIL 2025 75
TABLE 19 EMBECTA CORP.: BUSINESS OVERVIEW 77
TABLE 20 EMBECTA CORP.: PRODUCTS OFFERED 78
TABLE 21 EMBECTA CORP: PRODUCTS LAUNCHES & APPROVALS 79
TABLE 22 EMBECTA CORP: DEALS 79
TABLE 23 EMBECTA CORP: EXPANSIONS 80
TABLE 24 EMBECTA CORP.: OTHER DEVELOPMENTS 80
TABLE 25 NOVO NORDISK A/S: BUSINESS OVERVIEW 82
TABLE 26 NOVO NORDISK A/S: PRODUCTS OFFERED 83
TABLE 27 NOVO NORDISK A/S: PRODUCTS LAUNCHES & APPROVALS 84
TABLE 28 NOVO NORDISK A/S: DEALS 84
TABLE 29 NOVO NORDISK A/S: OTHER DEVELOPMENTS 86
TABLE 30 MEDTRONIC: BUSINESS OVERVIEW 88
TABLE 31 MEDTRONIC: PRODUCTS OFFERED 89
TABLE 32 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS 90
TABLE 33 MEDTRONIC: DEALS 91
TABLE 34 MEDTRONIC: EXPANSIONS 92
TABLE 35 MEDTRONIC: OTHER DEVELOPMENTS 92
TABLE 36 SANOFI: BUSINESS OVERVIEW 94
TABLE 37 SANOFI: PRODUCTS OFFERED 95
TABLE 38 SANOFI: PRODUCT LAUNCHES & APPROVALS 96
TABLE 39 SANOFI: EXPANSIONS 96
TABLE 40 SANOFI: OTHER DEVELOPMENTS 97
TABLE 41 ELI LILLY AND COMPANY: BUSINESS OVERVIEW 99
TABLE 42 ELI LILLY AND COMPANY: PRODUCTS OFFERED 100
TABLE 43 ELI LILLY AND COMPANY: PRODUCTS LAUNCHES 101
TABLE 44 ELI LILLY AND COMPANY: DEALS 101
TABLE 45 ELI LILLY AND COMPANY: EXPANSIONS 102
TABLE 46 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS 102
TABLE 47 TANDEM DIABETES CARE, INC.: BUSINESS OVERVIEW 104
TABLE 48 TANDEM DIABETES CARE, INC.: PRODUCTS OFFERED 105
TABLE 49 TANDEM DIABETES CARE, INC.: PRODUCTS LAUNCHES & APPROVALS 106
TABLE 50 TANDEM DIABETES CARE, INC.: DEALS 107
TABLE 51 INSULET CORPORATION: BUSINESS OVERVIEW 108
TABLE 52 INSULET CORPORATION: PRODUCTS LAUNCHES & APPROVALS 109
TABLE 53 INSULET CORPORATION: DEALS 111
TABLE 54 INSULET CORPORATION: EXPANSIONS 112
TABLE 55 INSULET CORPORATION: OTHER DEVELOPMENTS 112
TABLE 56 BIOCON: BUSINESS OVERVIEW 113
TABLE 57 BIOCON: PRODUCTS OFFERED 114
TABLE 58 BIOCON: DEALS 115
TABLE 59 BIOCON: OTHER DEVELOPMENTS 115
TABLE 60 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 116
TABLE 61 F. HOFFMANN-LA ROCHE: PRODUCTS OFFERED 117
TABLE 62 HOFFMANN-LA ROCHE LTD.: PRODUCTS LAUNCHES 118
TABLE 63 HTL-STREFA (SUBSIDIARY OF THE MTD GROUP): BUSINESS OVERVIEW 119
TABLE 64 HTL-STREFA (SUBSIDIARY OF THE MTD GROUP): PRODUCTS OFFERED 120
TABLE 65 HTL-STREFA (SUBSIDIARY OF THE MTD GROUP): DEALS 120
TABLE 66 YPSOMED: BUSINESS OVERVIEW 121
TABLE 67 YPSOMED: PRODUCTS OFFERED 122
TABLE 68 YPSOMED: PRODUCT LAUNCHES & APPROVALS 123
TABLE 69 YPSOMED: DEALS 124
TABLE 70 YPSOMED: EXPANSIONS 125
TABLE 71 YPSOMED: OTHER DEVELOPMENTS 126
TABLE 72 MEDTRUM TECHNOLOGIES INC.: BUSINESS OVERVIEW 127
TABLE 73 MEDTRUM TECHNOLOGIES INC.: PRODUCT PORTFOLIO 127
TABLE 74 TERUMO CORPORATION: BUSINESS OVERVIEW 128
TABLE 75 TERUMO CORPORATION: PRODUCTS OFFERED 129
TABLE 76 TERUMO CORPORATION: PRODUCT LAUNCHES 130
TABLE 77 TERUMO CORPORATION: DEALS 130
TABLE 78 TERUMO CORPORATION: EXPANSIONS 131
TABLE 79 TERUMO CORPORATION: OTHER DEVELOPMENTS 131
TABLE 80 WOCKHARDT LIMITED: BUSINESS OVERVIEW 132
TABLE 81 WOCKHARDT LIMITED: PRODUCTS OFFERED 133
TABLE 82 WOCKHARDT LIMITED: PRODUCTS LAUNCHES 133
TABLE 83 WOCKHARDT LIMITED: OTHER DEVELOPMENTS 134
TABLE 84 NIPRO: BUSINESS OVERVIEW 135
TABLE 85 NIPRO: PRODUCTS OFFERED 136
TABLE 86 NIPRO: EXPANSIONS 137
TABLE 87 RISK ASSESSMENT: INSULIN DELIVERY DEVICES MARKET 151
FIGURE 1 INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 15
FIGURE 2 INSULIN DELIVERY DEVICES MARKET, BY DISEASE TYPE,
2025 VS. 2030 (USD MILLION) 16
FIGURE 3 INSULIN DELIVERY DEVICES MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 16
FIGURE 4 GEOGRAPHICAL SNAPSHOT OF INSULIN DELIVERY DEVICES MARKET 17
FIGURE 5 INSULIN DELIVERY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 19
FIGURE 6 ESTIMATES OF GLOBAL PREVALENCE OF DIABETES IN
20-79-YEAR AGE GROUP, 2011-2024 (MILLION) 20
FIGURE 7 DIABETES AGE-STANDARDIZED PREVALENCE IN PEOPLE
(65-99 YEARS), BY REGION, 2024 AND 2050 (MILLION) 21
FIGURE 8 ADVANCEMENTS IN INSULIN DELIVERY DEVICES 22
FIGURE 9 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR
INSULIN DELIVERY DEVICES MARKET, JANUARY 2014-DECEMBER 2024 35
FIGURE 10 TOP PATENT APPLICANT COUNTRIES FOR INSULIN DELIVERY DEVICES,
JANUARY 2014-DECEMBER 2024 36
FIGURE 11 INSULIN DELIVERY DEVICE MARKET: ECOSYSTEM MAPPING 38
FIGURE 12 INSULIN DELIVERY DEVICES MARKET: PORTER'S FIVE FORCES ANALYSIS 39
FIGURE 13 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2022-2024 (USD MILLION) 45
FIGURE 14 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 46
FIGURE 15 INSULIN DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 49
FIGURE 16 INSULIN DELIVERY DEVICES MARKET: COMPANY FOOTPRINT, 2024 50
FIGURE 17 INSULIN DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 54
FIGURE 18 INSULIN DELIVERY DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 57
FIGURE 19 EV/EBITDA OF KEY VENDORS, 2024 58
FIGURE 20 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS, 2024 58
FIGURE 21 R&D ASSESSMENT OF KEY PLAYERS 59
FIGURE 22 EMBECTA CORP.: COMPANY SNAPSHOT, 2024 78
FIGURE 23 NOVO NORDISK A/S: COMPANY SNAPSHOT, 2024 83
FIGURE 24 MEDTRONIC: COMPANY SNAPSHOT, 2024 89
FIGURE 25 SANOFI: COMPANY SNAPSHOT, 2024 95
FIGURE 26 ELI LILLY AND COMPANY: COMPANY SNAPSHOT, 2024 100
FIGURE 27 TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT, 2024 105
FIGURE 28 INSULET CORPORATION: COMPANY SNAPSHOT, 2024 109
FIGURE 29 BIOCON: COMPANY SNAPSHOT, 2024 114
FIGURE 30 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT, 2024 117
FIGURE 31 YPSOMED: COMPANY SNAPSHOT, 2024 122
FIGURE 32 TERUMO CORPORATION: COMPANY SNAPSHOT, 2024 129
FIGURE 33 WOCKHARDT LIMITED: COMPANY SNAPSHOT, 2024 133
FIGURE 34 NIPRO: COMPANY SNAPSHOT, 2024 136
FIGURE 35 RESEARCH DESIGN 148
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security